Skip to search formSkip to main contentSkip to account menu

p21 N-Ras Protein

Known as: Proto-Oncogene Protein p21(c-N-ras), p21(N-ras), N-Ras Protein 
p21 N-RAS protein is encoded by the N-RAS gene. RAS proteins are involved in transmembrane signal transduction as monomeric GTP-binding proteins… 
National Institutes of Health

Related topics

Related topics

9 relations
GTP BindingGTP Binding DomainGuanosine Triphosphate PhosphohydrolasesMAPK Signaling Pathway

Broader (1)

Proto-Oncogene Proteins p21(ras)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract 4635: Comparative cancer cell line profiling differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors
[purpose] Profiling of drug candidates in cell line panels is an important tool to compare the selectivity and targeting of new… 
2016
2016
NRAS Isoform 5
2015
2015
Survival in glioblastoma patients is predicted by miR-340, that regulates key cancer hallmarks by inhibiting NRAS
Glioblastoma (GBM) is the most common primary brain tumor in adults, with a poor prognosis and a survival rate of only 12 months… 
2014
2014
Signal Transduction Targeting TBK 1 Inhibits Migration and Resistance to MEK Inhibitors in Mutant NRAS Melanoma
Melanoma is a devastating form of skin cancer with limited therapeutic options. Fifteen to 20% of patients with melanoma have an… 
2013
2013
Chemical Therapeutics Inhibition of Wee 1 , AKT , and CDK 4 Underlies the Ef fi cacy of the HSP 90 Inhibitor XL 888 in an In Vivo Model of NRAS-Mutant Melanoma
The HSP90 inhibitor XL888 is effective at reversing BRAF inhibitor resistance in melanoma, including that mediated through… 
2013
2013
The role of MIF in melanoma progression
.......................................... ..................................................................................... XVI CHAPTER 1 .................................................................................................................................. 1 1.1 MELANOMA .......................................................................................................................... 2 1.1.1 Epidemiology .................................................................................................................. 2 1.1.2 Etiology and Risk Factors ............................................................................................... 5 1.1.3 Pathology of Melanocytic Tumours ................................................................................ 7 1.1.4 Staging and Prognosis ................................................................................................... 9 1.1.5 Treatment ..................................................................................................................... 11 1.2 SIGNALLING NETWORKS IN MELANOMA ................................................................................ 12 1.2.1 BRAF and MAPK/ERK signalling pathway ................................................................... 12 1.2.2 PTEN and the Akt signalling pathway .......................................................................... 16 1.2.3 NRAS mutations ........................................................................................................... 17 1.2.4 Autocrine signalling....................................................................................................... 20 1.3 MIF ................................................................................................................................... 21 1.3.1 MIF in Melanoma .......................................................................................................... 22 1.3.2 MIF signalling ................................................................................................................ 23 1.4 CD74 ................................................................................................................................ 23 1.5 CD44 ................................................................................................................................ 25 1.5.1 CD44 in cancer ............................................................................................................. 27 
2012
2012
Corrigendum: Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Nat. Med. 18, 1503–1510 (2012); published online 16 September 2012; corrected after print 20 November 2012 In the version of this… 
2012
2012
Preclinical Development Combinations of BRAF , MEK , and PI 3 K / mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK 2118436 Dabrafenib , Mediated by NRAS or MEK Mutations
Recent results from clinical trials with the BRAF inhibitors GSK2118436 (dabrafenib) and PLX4032 (vemurafenib) have shown… 
2010
2010
Clinical outcome and pathologic features associated with NRAS mutation in cutaneous melanoma.
8500 Background: Mutations in NRAS and BRAF are common in cutaneous melanoma leading to constitutive activation of the MAPK… 
2003
2003
NRAS hypermutability in familial melanoma with CDKN2A mutations--cause and effect?
The frequency of cutaneous melanoma has been increasing worldwide for several decades. Approximately 8%–12% of melanomas occur in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)